Nabriva: Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study

-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone

-Nabriva awarded grant…

MedUni Vienna: Obesity: genetic factors influence eating behaviour

People who are genetically predisposed to being overweight have a much harder time keeping their weight. A research team…

Coronavirus: EU unterstützt Impfstoff-Forschung mit zusätzlichen 100 Millionen Euro

Die Kommission beteiligt sich mit weiteren 100 Mio. Euro an der raschen Entwicklung von Coronavirus-Impfstoffen. Mit den…

Valneva Announces Positive Initial Results for Phase 2 Study of Lyme Disease Vaccine Candidate

- Phase 2 study VLA15-201 met its endpoints

- Compared to Phase 1, the higher doses used in this trial elicited higher…

Österreichischer Health-Tech Pionier myBioma sichert sich sechsstelliges follow-up Investment

Das Health-Tech Start-Up myBioma hat die Corona-Krise als Chance gesehen und genutzt. Neben einer erfolgreichen…

MedUni Vienna: Novel therapeutic approaches for aggressive bone cancer

MedUni Vienna study enhances understanding of osteosarcoma disease mechanisms


The new start-up QUANTRO Therapeutics at the Vienna BioCenter uses innovative transcriptome profiling technologies in a…

CEPI extends funding call to accelerate development and global manufacture of COVID-19 vaccines

- CEPI has extended its Call for Proposals to advance development and manufacture of COVID-19 vaccine candidates


QUANTRO Therapeutics Launched with Breakthrough Oncology Drug Discovery Platform

- QUANTRO to enable discovery of novel therapeutics that interfere with disease-causing transcriptional programs in…

Uni Wien: Weniger Spielraum als gedacht: Mikrowelt im Boden beschleunigt Klimawandel

Erstmals Einfluss des Priming-Effekts in der Arktis auf den Klimawandel berechnet

MedUni Vienna: Premature babies: high exposure to noise in the incubator

"Sounds of Silence" study – making incubator noises audible

Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program

Valneva SE, a specialty vaccine company focused on prevention against diseases with major unmet needs, today confirmed…

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)